Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Journal of Theoretical Biology
|
February 6, 2025
Simulations probe the role of space in the interplay between drug-sensitive and drug-resistant cancer cells
Kira Pugh, Rhys D O Jones, Gibin Powathil, et al.
Plos One
|
May 17, 2023
Interspecies evaluation of a physiologically based pharmacokinetic model to predict the biodistribution dynamics of dendritic nanoparticles
Christina Vasalou, Joanna Harding, Rhys D O Jones, et al.
Drug Discovery Today
|
August 13, 2017
Developing PreDICT - a fully integrated data platform for preclinical in vivo data: learning from experience
Rhys D O Jones, Marie Cooke, James Hinchliffe, et al.
Molecular Cancer Therapeutics
|
March 8, 2023
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model
Rhys D O Jones, Klas Petersson, Areya Tabatabai, et al.
Clinical and Translational Science
|
November 10, 2025
Predicting the Pharmacokinetics of T-Cell Engagers as a Function of Target-Mediated Drug Disposition
Mark Penney, Alberto Ippolito, Elisa Fevola, et al.
Trends in Pharmacological Sciences
|
May 4, 2020
Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades
Michael Davies, Rhys D O Jones, Ken Grime, et al.
Communications Biology
|
November 6, 2025
A mismatch in enzyme-redox partnerships underlies divergent cytochrome P450 activities between human hepatocytes and microsomes
Tashinga E Bapiro, Scott Martin, Thomas S Blacker, et al.
The AAPS Journal
|
June 28, 2023
A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse Models
Michael J White, Letitia Cheatham, Shenghua Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Venkatesh Pilla Reddy, Rana Anjum, Michael Grondine, et al.
British Journal of Pharmacology
|
October 30, 2020
A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activity
Rhys D O Jones, Mike Grondine, Alexandra Borodovsky, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Journal of Theoretical Biology
|
February 6, 2025
Simulations probe the role of space in the interplay between drug-sensitive and drug-resistant cancer cells
Kira Pugh, Rhys D O Jones, Gibin Powathil, et al.
Plos One
|
May 17, 2023
Interspecies evaluation of a physiologically based pharmacokinetic model to predict the biodistribution dynamics of dendritic nanoparticles
Christina Vasalou, Joanna Harding, Rhys D O Jones, et al.
Drug Discovery Today
|
August 13, 2017
Developing PreDICT - a fully integrated data platform for preclinical in vivo data: learning from experience
Rhys D O Jones, Marie Cooke, James Hinchliffe, et al.
Molecular Cancer Therapeutics
|
March 8, 2023
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model
Rhys D O Jones, Klas Petersson, Areya Tabatabai, et al.
Clinical and Translational Science
|
November 10, 2025
Predicting the Pharmacokinetics of T-Cell Engagers as a Function of Target-Mediated Drug Disposition
Mark Penney, Alberto Ippolito, Elisa Fevola, et al.
Trends in Pharmacological Sciences
|
May 4, 2020
Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades
Michael Davies, Rhys D O Jones, Ken Grime, et al.
Communications Biology
|
November 6, 2025
A mismatch in enzyme-redox partnerships underlies divergent cytochrome P450 activities between human hepatocytes and microsomes
Tashinga E Bapiro, Scott Martin, Thomas S Blacker, et al.
The AAPS Journal
|
June 28, 2023
A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse Models
Michael J White, Letitia Cheatham, Shenghua Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Venkatesh Pilla Reddy, Rana Anjum, Michael Grondine, et al.
British Journal of Pharmacology
|
October 30, 2020
A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activity
Rhys D O Jones, Mike Grondine, Alexandra Borodovsky, et al.
Page
of 2